RxDoctor Payments Data

Girma Assefa, MD

Internal Medicine · South Holland, ILNPI 1619904992

Payments from drug & device makers

$398in general payments, 2019–2025

Across 20 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$131
  • GSK$101
  • Lilly USA, LLC$44
  • Bayer$35
  • Dexcom, Inc.$31
  • Abbott$30
  • plus $27 from 1 others

What the payments were for

  • Food & beverage$398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$131
GSK6$101
Lilly USA, LLC2$44
Bayer2$35
Dexcom, Inc.1$31
Abbott1$30
Exact Sciences1$27

How this compares

$398 in reported general payments places this provider in the 65th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$81,408
Medicare patients
218
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin167$214,968
OzempicSemaglutide126$139,132
EliquisApixaban109$126,973
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$121,870
FarxigaDapagliflozin Propanediol102$100,646
JanuviaSitagliptin Phosphate57$75,580
XareltoRivaroxaban65$67,558
RybelsusSemaglutide28$63,917
Tresiba Flextouch U-100Insulin Degludec102$63,868
TradjentaLinagliptin38$54,955
Breo ElliptaFluticasone/Vilanterol88$52,086
EntrestoSacubitril/Valsartan28$41,744
TrulicityDulaglutide21$28,644
Tresiba Flextouch U-200Insulin Degludec23$23,238
MyrbetriqMirabegron21$19,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$131$203,049154 claims
GSKTrelegy Ellipta, Breo Ellipta$101$173,956223 claims
Lilly USA, LLCTrulicity$44$28,64421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in South Holland

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →